2 research outputs found
Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination
Innovative and efficient hit-identification techniques are required to
accelerate drug discovery. Protein-templated fragment ligations
represent a promising strategy in early drug discovery, enabling the
target to assemble and select its binders from a pool of building
blocks. Development of new protein-templated reactions to access
a larger structural diversity and expansion of the variety of targets
to demonstrate the scope of the technique are of prime interest for
medicinal chemists. Herein, we present our attempts to use a
protein-templated reductive amination to target protein-protein
interactions (PPIs), a challenging class of drug targets. We address a
flexible pocket, which is difficult to achieve by structure-based drug
design. After careful analysis we did not find one of the possible
products in the kinetic target-guided synthesis (KTGS) approach,
however subsequent synthesis and biochemical evaluation of each
library member demonstrated that all the obtained molecules
inhibit MDM2. The most potent library member (Ki=0.095 ÎĽm)
identified is almost as active as Nutlin-3, a potent inhibitor of the
p53-MDM2 PPI
Optimized Inhibitors of MDM2 via an Attempted Protein-Templated Reductive Amination.
Innovative and efficient hit-identification techniques are required to accelerate drug discovery. Protein-templated fragment ligations represent a promising strategy in early drug discovery, enabling the target to assemble and select its binders from a pool of building blocks. Development of new protein-templated reactions to access a larger structural diversity and expansion of the variety of targets to demonstrate the scope of the technique are of prime interest for medicinal chemists. Herein, we present our attempts to use a protein-templated reductive amination to target protein-protein interactions (PPIs), a challenging class of drug targets. We address a flexible pocket, which is difficult to achieve by structure-based drug design. After careful analysis we did not find one of the possible products in the kinetic target-guided synthesis (KTGS) approach, however subsequent synthesis and biochemical evaluation of each library member demonstrated that all the obtained molecules inhibit MDM2. The most potent library member (Ki =0.095 μm) identified is almost as active as Nutlin-3, a potent inhibitor of the p53-MDM2 PPI